Take­da spin­out Hill­e­Vax de­lays PhI­Ib norovirus topline da­ta un­til mid-2024 over pro­cess­ing lo­gis­tics

Take­da spin­out Hill­e­Vax has de­layed topline da­ta from its Phase IIb norovirus vac­cine tri­al un­til mid-2024, the com­pa­ny an­nounced Mon­day in its sec­ond-quar­ter fi­nan­cial re­sults. It was ini­tial­ly slat­ed for the first quar­ter of 2024.

The tri­al is de­layed be­cause of prob­lems “re­lat­ing sole­ly to the lo­gis­ti­cal com­plex­i­ty of pro­cess­ing di­ar­rheal sam­ples from var­i­ous ge­o­gra­phies,” Hill­e­Vax CEO Rob Her­sh­berg said in a state­ment. Com­pa­ny man­age­ment told an­a­lysts from Leerink Part­ners that Hill­e­Vax won’t know how many ac­crued cas­es there are due to norovirus and which strains un­til sam­ple pro­cess­ing pro­gress­es in the tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER